Benzinga | Jul 19, 2021 08:02AM EDT

VYNE Therapeutics Announces Initiation Of Investigator-Initiated Trial Evaluating AMZEEQ With Oral Isotretinoin In Patients With Moderate To Severe Acne

VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced the initiation of an investigator initiated trial ("IIT" or "study") evaluating the safety and efficacy of AMZEEQ(r) (minocycline) topical foam, 4%, as a companion treatment with oral isotretinoin in patients with moderate to severe acne. The study is supported by VYNE and is being conducted by the Austin Institute for Clinical Research in Texas.

"Isotretinoin has been widely used for the management of severe or scarring acne since its introduction as Accutane(r) in the 1980s. However, its teratogenic properties means that patients must be monitored very carefully and its use as a chronic treatment is limited," said Dr. Edward Lain, MD MBA FAAD, practicing dermatologist at Sanova Dermatology in Austin, Texas, and Principal Investigator for the study. "The combination of an oral isotretinoin and a topical minocycline presents a combined proposition of achieving control of severe disease coupled with long-term disease management possibilities," he said. Dr. Lain also served as an investigator in the clinical trials for AMZEEQ and is a consultant to VYNE.

"AMZEEQ is a valuable topical treatment option for moderate to severe acne. As a single agent, it has demonstrated strong efficacy as well as a very favorable side effect profile. We are pleased that AMZEEQ is also receiving interest from the dermatology community to study AMZEEQ as part of a combination regimen with oral isotretinoin for both acute and chronic management of the disease," said Dr. Iain Stuart, Chief Scientific Officer of VYNE.